294 related articles for article (PubMed ID: 17573125)
1. Constitutive activity of the histamine H3 receptor.
Arrang JM; Morisset S; Gbahou F
Trends Pharmacol Sci; 2007 Jul; 28(7):350-7. PubMed ID: 17573125
[TBL] [Abstract][Full Text] [Related]
2. High constitutive activity of native H3 receptors regulates histamine neurons in brain.
Morisset S; Rouleau A; Ligneau X; Gbahou F; Tardivel-Lacombe J; Stark H; Schunack W; Ganellin CR; Schwartz JC; Arrang JM
Nature; 2000 Dec; 408(6814):860-4. PubMed ID: 11130725
[TBL] [Abstract][Full Text] [Related]
3. [The histamine H(3) receptor: a target for new drugs].
Arrang JM
Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
[TBL] [Abstract][Full Text] [Related]
4. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Gbahou F; Davenas E; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
[TBL] [Abstract][Full Text] [Related]
5. Protean agonism at histamine H3 receptors in vitro and in vivo.
Gbahou F; Rouleau A; Morisset S; Parmentier R; Crochet S; Lin JS; Ligneau X; Tardivel-Lacombe J; Stark H; Schunack W; Ganellin CR; Schwartz JC; Arrang JM
Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11086-91. PubMed ID: 12960366
[TBL] [Abstract][Full Text] [Related]
6. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists.
Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R
J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875
[TBL] [Abstract][Full Text] [Related]
7. No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers.
Schnell D; Burleigh K; Trick J; Seifert R
J Pharmacol Exp Ther; 2010 Mar; 332(3):996-1005. PubMed ID: 19959746
[TBL] [Abstract][Full Text] [Related]
8. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
9. The H3 receptor protean agonist proxyfan enhances the expression of fear memory in the rat.
Baldi E; Bucherelli C; Schunack W; Cenni G; Blandina P; Passani MB
Neuropharmacology; 2005 Feb; 48(2):246-51. PubMed ID: 15695163
[TBL] [Abstract][Full Text] [Related]
10. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
[TBL] [Abstract][Full Text] [Related]
11. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of highly constitutive active histamine H3 receptors.
Takahashi K; Tokita S; Kotani H
J Pharmacol Exp Ther; 2003 Oct; 307(1):213-8. PubMed ID: 12954820
[TBL] [Abstract][Full Text] [Related]
13. [The histaminergic system: a target for innovative treatments of cognitive deficits].
Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
[TBL] [Abstract][Full Text] [Related]
14. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
15. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18.
Hamill TG; Sato N; Jitsuoka M; Tokita S; Sanabria S; Eng W; Ryan C; Krause S; Takenaga N; Patel S; Zeng Z; Williams D; Sur C; Hargreaves R; Burns HD
Synapse; 2009 Dec; 63(12):1122-32. PubMed ID: 19670309
[TBL] [Abstract][Full Text] [Related]
16. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
Mezzomo K; Cumming P; Minuzzi L
Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
[TBL] [Abstract][Full Text] [Related]
19. H3 receptor antagonists/inverse agonists as anti-obesity agents.
Hancock AA
Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
[TBL] [Abstract][Full Text] [Related]
20. Cloning and characterization of the monkey histamine H3 receptor isoforms.
Strakhova MI; Fox GB; Carr TL; Witte DG; Vortherms TA; Manelli AM; Miller TR; Yao BB; Brioni JD; Esbenshade TA
Eur J Pharmacol; 2008 Dec; 601(1-3):8-15. PubMed ID: 18977214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
